N-acetilcysteine prevents the <i>A</i>. <i>simplex</i> CE-induced TEER decrease. by Noelia Carballeda-Sangiao (2889611)

JNJ26993135 + BML-111 decreases permeability and enhances ZO-1 and claudin-1 induced by PAF but does not change TEER. by Kameljit K. Kalsi (16496511)

Transepithelial electrical resistance (TEER) (N = 6). by Shirko Marcel Shokr (19173337)

“…<p><b>(A)</b> During the cultivation of SMC and ALI we observed significantly differences on day 18 (SMC: 9.61 kΩ*cm²; ALI: 7.73 kΩ*cm²; p<0.05) and day 25 (SMC: 8.19 kΩ*cm²; ALI: 6.44 kΩ*cm²; p<0.05) ALI cultures showed significantly decreased values compared to SMC. …”

Viloxazine Extended-Release: A Review of in Attention-Deficit/Hyperactivity Disorder in Adults by Yahiya Y. Syed (6594444)

“…</p><p><br></p><p dir="ltr"><b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</b> not applicable</p><p><br></p><p dir="ltr">Additional information about this Adis Drug Review can be found <a href="https://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank">here</a></p><p><br></p><p dir="ltr"><b>Abstract</b></p><p dir="ltr">An extended-release once-daily oral capsule formulation of viloxazine (viloxazine ER; Qelbree®), a norepinephrine reuptake inhibitor and serotonin receptor modulator, has been approved in the USA for the treatment of attention-deficit/hyperactivity disorder (ADHD) in paediatric patients and adults. …”

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Sodium oxybate extended-release suspension (LUMRYZ™) in narcolepsy: a profile of its use by Hannah A. Blair (13864794)

“…</p> <p><br></p> <p>  </p> <p><strong>Abstract </strong>Sodium oxybate extended-release suspension (LUMRYZ™; hereafter referred to as sodium oxybate ER) represents a promising novel option for the treatment of narcolepsy. …”

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

GXM decreases the trans-endothelial electrical resistance (TEER) and transmigration of <i>C</i>. <i>neoformans</i> through HBECs in a blood brain barrier (BBB) model. by Hiu Ham Lee (15374677)

Comparison of different fibre release and placement options. by Adrianne L. Jenner (11133854)

Subjects:

Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review by Cayley Russell (8087372)

“…Among other barriers, daily dosing requirements hinder treatment continuity post-release. Extended-release buprenorphine (XR-BUP) may therefore be beneficial. …”

Effect of extended-release buprenorphine (1 mg/kg SC) on tactile hypersensitivity in a rat model of inflammation. by Christina M. Larson (18196213)

“…<p>The mechanical nociceptive threshold is transiently changed by extended-release buprenorphine. Initial hypersensitivity tested at time point 0 was compared to time points following administration of extended-release buprenorphine (Bupe ER). …”

BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)

DataSheet1_Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.zip by Chen Qi Zhang (12398296)

“…<p>Purpose: A novel once-daily divalproex-extended release (ER) dose formulation has been developed; this formulation prolongs the therapeutic serum levels of the drug, compared with the twice-daily conventional divalproex-delayed release (DR) formulation. …”

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Effect of extended-release buprenorphine (1 mg/kg SC) as compared to saline control on tactile hypersensitivity in a model of inflammatory hypersensitivity in rats. by Christina M. Larson (18196213)

“…A) In both male and female subjects analyzed together, there is significant elevation of mechanical thresholds for rats treated with extended-release buprenorphine (Bupe ER) as compared to rats treated with saline following induction of inflammation via intraplantar CFA. …”

Effect of extended-release buprenorphine (1 mg/kg, SC) as compared to saline control on tactile hypersensitivity in an incisional model of post-operative pain in the rat. by Christina M. Larson (18196213)

“…<p>The mechanical nociceptive thresholds in subjects given extended-release buprenorphine are not significantly different from those in subjects given saline. …”

<b>Extended Osteoarthritis Pain Relief with Neosaxitoxin using Alginate-core Polymeric Microparticles</b> by Hengli Zhang (21602333)

Table 1_Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia.docx by Zheng Lan (21451100)

“…Participants were randomized (1:1) to receive either paliperidone extended-release (ER) tablets (titrated 3–12 mg/day) or PP1M (3–9 mg monthly). …”

Supplementary Material for: Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Months Naturalistic Study by Brenna I.H. (19773549)

“…ABSTRACT Introduction The treatment efficacy of extended-release naltrexone (XR-NTX) for opioid use disorder (OUD) has been demonstrated in several studies, but not in naturalistic settings where opioid agonist treatment (OAT) is freely accessible. …”